AI assistant
Bliss GVS Pharma Limited — Board/Management Information 2021
May 11, 2021
61284_rns_2021-05-11_f9c91310-a6ee-4053-9b85-03cbfb9e6f80.pdf
Board/Management Information
Open in viewerOpens in your device viewer
BLISS GVS PHARMA LTD. ca.s.s

May ll, 2021
Dear Sir/Madam,
Subject: Outcome of Board Meeting held on Tuesday, May 11, 2021
We would like to inform you that, the Board Meeting of the Company was held today i.e. Tuesday, May 11, 2021 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matters:
-
- The Audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2021 along with the audit report of the auditors. The copy of said financial results and audit reports are enclosed herewith as' Annexure -1';
-
- Declaration of unmodified opinion for annual audited standalone and consolidated financial results for the year ended March 31, 2021 in accordance with Regulation 33(3)( d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016 is enclosed herewith as 'Annexure - 2';
-
- Recommended Final dividend of 50% i.e. 0.50 paisa per equity share on face value of Rs. 1/ each for the financial year ended March 31, 2021, subject to approval of the shareholders in the forthcoming Annual General Meeting of the Company;
-
- Re-appointment of M/ s. BDO India LLP, Chartered Accountant having LLP registration no. AAB-7880 as Internal Auditor of the Company for the financial year 2021-22. The brief profile

Factory: Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA. TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930, Email: [email protected] ·Website: www.blissgvs.com • CIN - L24230MH1984PLC034771 Plot No. 10 & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tai. & Dist. Palghar - 401 404. Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email : [email protected]

- Issue & Allotment of 2,10,500 Equity Shares of face value of Rs. 1 each of the Company under 'Bliss GVS Pharma Limited-Employee Stock Option Plan 2019' ('Bliss GVS ESOP-2019') to the eligible employees under the said Plan, pursuant to exercise of stock options granted thereunder.
Consequent to the aforesaid allotment, Issued, subscribed & paid-up share capital of the Company has increased as under:
| From | To |
|---|---|
| 10,31,46,672 equity shares of Re.1 each | 10,33,57,172 equity shares of Re.l each |
| aggregating Rs. 10,31,46,672/- | aggregating Rs. 10,33,57,172 / - |
In terms of Regulation lO(c) of the SEBI (Share Based Employee Benefits) Regulations, 2014 (SEBI SBEB Regulations) read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015 the details of shares allotted as above are given in' Annexure-4';
-
- Re-appointment of Mr. Santosh Laxman Parab (DIN:01622988), as an Non-Executive Independent Director of the Company for a further period of 5 years with effect from 26th May, 2021 to 25th May, 2026, subject to the approval of members in the ensuing Annual General Meeting. The brief profile of Mr. Santosh Laxman Parab is enclosed herewith as 'Annexure-5';
-
- Resignation of Mr.SN Kama th from the position of Managing Director as well as membership from all conunittees of board of the Company with inunediate effect i.e. May 11, 2021;
-
- Appointment of Mr. Gagan Harsh Sharma (DIN:07939421) as Managing Director of the Company for a period of Three years with effect from 11th May, 2021 to 10th May, 2024, subject to the approval of members in the ensuing Annual General Meeting. The brief profile is enclosed herewith as' Annexure-6'.
-
- The Board reconstituted the following conunittees:
- a. Audit Committee
- b. Corporate Social Responsibility Committee
The Reconstitution is enclosed herewith as' Annexure -7'.

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA. TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930, Email: [email protected] •Website: www.blissgvs.com • CIN - L24230MH1984PLC034771 Factory : Plot No. 1 O & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tai. & Dist. Palghar - 401 404. Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email : [email protected]
BLISS GVS PHARMA LTD.

The meeting of the Board of Directors conunenced at 12:30 p.m. and concluded at 07:20 p.m. Kindly take the above information on your record and acknowledge.
Thanking you.
Your Faithfully,
Encl: As abov For Bliss GV Pharma Limited
Factory: Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East}, Mumbai - 400 072, INDIA. TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930, Email: [email protected] •Website: www.blissgvs.com • CIN - L24230MH1984PLC034771 Plot No. 10 & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tai. & Dist. Palghar - 401 404. Tel. (+91) (02525) 252713 • Fax: (+91) (02525} 255257. • Email :·[email protected]

'Annexure - 4'
Regulation lO(c) of the SEBI (Share Based Employee Benefits) Regulations, 2014
| and Company Name address of |
Bliss GVS Pharma Limited |
|---|---|
| Registered Office | Add: 102, Hyde Park, Sakivihar Road, |
| Andheri (East), Mumbai - 400072 | |
| Name of the Stock Exchanges on which | BSE Limited |
| the Company's shares are listed | The National Stock Exchange of India |
| Limited | |
| Filing date of the statement referred in | 14/02/2020 |
| regulation lO(b) of the SEBI (Share Based | |
| Benefits) Regulations, Employee 2014 |
|
| with Stock Exchange | |
| Filing Number, if any | Application No: |
| BSE -106063 | |
| NSE-23188 | |
| In-Principle Approval Letter: | |
| BSE: DCS/FL/DS/ESOP-IP /542/2019-20 | |
| dated February 27, 2020 NSE: NSE/LIST/2 dated March 04, |
|
| 3188 2020 |
|
| Title of the Scheme pursuant to which | Pharma Limited-Employee Bliss GVS |
| shares are issued, if any | Stock Option Plan 2019 |
| Kind of security to be listed | Equity Shares |
| Par value of the shares | Rs. 1 / - Per Share |
| Date of issue of shares | May 11, 2021 |
| Number of shares issued | 2,10,500 |
| Share Certificate No., if applicable | Not Applicable |
| share, Distinctive number the if of applicable |
to (both 10,31,46,672 10,33,57,172 |
| inclusive) | |
| ISIN Number of the shares if issued in | INE416D01022 |
| Demat | |
| Exercise price per share | Rs.43 per share |
| Premium per share | Rs.42 per share |


| Total Issued shares after this issue | 10,33,57,172 |
|---|---|
| Total Issued share capital after this issue | Rs.10,33,57,172/- |
| Details of any lock-in on the shares | Lock in for a period of 6 (six) months from |
| the date of allotment of Equity Shares. | |
| Date of expiry of lock-in | 10th November, 2021 |
| Whether shares identical in all respects to | All equity shares of the Company allotted |
| if not, when will they shares existing |
pursuant to exercise of stock options shall |
| become identical? | rank pari-passu with the existing equity |
| shares of the Company | |
| Details of listing fees, if payable | Not applicable |
Relevant disclosures as per SEBI circular CIR/CFD/CMD/4/2015 dated September 9, 2015
| Options Vested | 690,250 Equity Shares |
|---|---|
| Time within which option be may |
Within a period of 6 (Six) months from the |
| exercised | date of vesting of such options. |
| Options exercised | 2,10,500 Equity Shares |
| Money realized by exercise of options | Rs.90,51,500/- |
| The total number of shares arising as |
2,10,500 Equity Shares |
| result of exercise of option | |
| Options lapsed | - |
| per share pursuant to Diluted earnings |
Rs.6.53 per share |
| issue of equity shares exercise on of |
|
| options | |
| Whether the scheme is in terms of SEBI Yes | |
| (SBEB) Regulations, 2014 |